ArticleInternational journal of molecular sciences2025

A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC.

Mark Spivak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.